Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Total Liabilities of $5.7 million for Q1 2026, down 33.2% year-over-year from $8.6 million in Q1 2025, and down 31.19% quarter-over-quarter from $8.3 million in Q4 2025.
Inhibikase Therapeutics (IKT) Total Liabilities (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Total Liabilities for 7 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 33.2% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 33.2% YoY), while the FY2025 annual figure was $8.3 million, up 122.33% from the prior year.
- Total Liabilities declined to $5.7 million in Q1 2026 per IKT's latest filing, from $8.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $8.8 million in Q2 2025 and bottomed at $2.8 million in Q1 2023.
- Historically, Total Liabilities has averaged $4.9 million across 5 years, with a median of $4.3 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities slumped 35.79% — and 2025, when it jumped 135.9%.
- Inhibikase Therapeutics' Total Liabilities stood at $3.9 million in 2022, then retreated by 9.54% to $3.5 million in 2023, then rose by 5.8% to $3.7 million in 2024, then jumped by 122.33% to $8.3 million in 2025, then sank by 31.19% to $5.7 million in 2026.
- Business Quant data shows IKT's Total Liabilities at $5.7 million in Q1 2026, $8.3 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 10.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.26 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Dec 31, 2025 | 8.30 Mn |
| Sep 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 8.80 Mn |
| Mar 31, 2025 | 8.55 Mn |
| Dec 31, 2024 | 3.73 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Mar 31, 2024 | 4.29 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Jun 30, 2023 | 2.88 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | 3.90 Mn |
| Sep 30, 2022 | 3.45 Mn |
| Jun 30, 2022 | 4.49 Mn |
| Mar 31, 2022 | 4.38 Mn |
| Dec 31, 2021 | 4.05 Mn |
| Sep 30, 2021 | 2.71 Mn |